The Incidence and Risk of Venous Thromboembolism Associated With Cancer and Nonsurgical Cancer Treatment

REFERENCES

• Khorana A. A., Francis C. W., Culakova E., Kuderer N. M., Lyman G. H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339–2346
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Levine M. N. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107(23 Suppl 1)I17–I21
   PubMed Web of Science ®Google Scholar
• Heit J. A., Silverstein M. D., Mohr D. N., Petterson T. M., O'Fallon W.M., Melton L. J., 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809–815
   PubMed Web of Science ®Google Scholar
• Alikhan R., Cohen A. T., Combe S., Samama M. M., Desjardins L., Eldor A., et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 2004; 164: 963–968
   PubMed Web of Science ®Google Scholar
• Heit J. A., O'Fallon W.M., Petterson T. M., Lohse C. M., Silverstein M. D., Mohr D. N., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245–1248
   PubMed Web of Science ®Google Scholar
• Spencer F. A., Lessard D., Emery C., Reed G., Goldberg R. J. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167: 1471–1475
   PubMed Web of Science ®Google Scholar
• Imberti D., Agnelli G., Ageno W., Moia M., Palareti G., Pistelli R., et al. MASTER Investigators. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER registry. Haematologica 2008; 93: 273–278
   PubMed Web of Science ®Google Scholar
• Seddighzadeh A., Shetty R., Goldhaber S. Z. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007; 98: 656–661
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Fisher R. I., Kuderer N. M., Lyman G. H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484–490
   PubMed Web of Science ®Google Scholar
• Agnelli G., Bolis G., Capussotti L., Scarpa R. M., Tonelli F., Bonizzoni E., et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243: 89–95
   PubMed Web of Science ®Google Scholar
• Lyman G. H., Khorana A. A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490–5505
   PubMed Web of Science ®Google Scholar
• Geerts W. H., Bergqvist D., Pineo G. F., Heit J. A., Samama C. M., Lassen M. R., et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(6 Suppl)381S–453S
   PubMed Web of Science ®Google Scholar
• Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–722
   PubMed Web of Science ®Google Scholar
• Levitan N., Dowlati A., Remick S. C., Tahsildar H. I., Sivinski L. D., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using medicare claims data. Medicine (Baltimore) 1999; 78: 285–291
   PubMed Web of Science ®Google Scholar
• Sallah S., Wan J. Y., Nguyen N. P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575–579
   PubMed Web of Science ®Google Scholar
• Stein P. D., Beemath A., Meyers F. A., Skaf E., Sanchez J., Olson R. E. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60–68
   PubMed Web of Science ®Google Scholar
• Storto M. L., Di Credico A., Guido F., Larici A. R., Bonomo L. Incidental detection of pulmonary emboli on routine MDCT of the chest. AJR Am J Roentgenol 2005; 184: 264–267
   PubMed Web of Science ®Google Scholar
• Sebastian A. J., Paddon A. J. Clinically unsuspected pulmonary embolism—an important secondary finding in oncology CT. Clin Radiol 2006; 61: 81–85
   PubMed Web of Science ®Google Scholar
• O'Connell C.L., Boswell W. D., Duddalwar V., Caton A., Mark L. S., Vigen C., et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 2006; 24: 4928–4932
   PubMed Web of Science ®Google Scholar
• Hutten B. A., Prins M. H., Gent M., Ginsberg J., Tijssen J. G.P., Büller H. R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio. J Clin Oncol 2000; 18: 3078–3083
   PubMed Web of Science ®Google Scholar
• Prandoni P., Lensing A. W., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–3488
   PubMed Web of Science ®Google Scholar
• Chew H. K., Wun T., Harvey D., Zhou H., White R. H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458–464
   PubMed Web of Science ®Google Scholar
• Sørensen H.T., Mellemkjaer L., Olsen J. H., Baron J. A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846–1850
   PubMed Web of Science ®Google Scholar
• Alcalay A., Wun T., Khatri V., Chew H. K., Harvey D., Zhou H., et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006; 24: 1112–1118
   PubMed Web of Science ®Google Scholar
• Alikhan R., Peters F., Wilmott R., Cohen A. T. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol 2004; 57: 1254–1257
   PubMed Web of Science ®Google Scholar
• Monreal M., Falgá C., Valdés M., Suárez C., Gabriel F., Tolosa C., et al. for the Riete Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4: 1950–1956
   PubMed Web of Science ®Google Scholar
• Muñoz F. J., Mismetti P., Poggio R., Valle R., Barrón M., Guil M., et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133: 143–148
   PubMed Web of Science ®Google Scholar
• Semrad T. J., O'Donnell R., Wun T., Chew H., Harvey D., Zhou H., et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106: 601–608
   PubMed Web of Science ®Google Scholar
• Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005; 31: 104–110
   PubMed Web of Science ®Google Scholar
• Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723–1729
   PubMed Web of Science ®Google Scholar
• Furie B., Furie B. C. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938–949
   PubMed Web of Science ®Google Scholar
• Rickles F. R., Levine M. N. Epidemiology of thrombosis in cancer. Acta Haematol. 2001; 106: 6–12
   PubMed Web of Science ®Google Scholar
• Falanga A. Thrombosis and malignancy: an underestimated problem. Haematologica 2003; 88: 607–610
   PubMedGoogle Scholar
• Blom J. W., Vanderschoot J. P., Oostindier M. J., Osanto S., van der Meer F.J., Rosendaal F. R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4: 529–535
   PubMed Web of Science ®Google Scholar
• Thodiyil P. A., Kakkar A. K. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002; 87: 1076–1077
   PubMed Web of Science ®Google Scholar
• Mandala M., Falanga A., Piccioli A., Prandoni P., Pogliani E. M., Labianca R., et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006; 59: 194–204
   PubMed Web of Science ®Google Scholar
• Levine M. N., Gent M., Hirsh J., Arnold A., Goodyear M. D., Hryniuk W., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404–407
   PubMed Web of Science ®Google Scholar
• Cheruku R., Tapazoglou E., Ensley J., Kish J. A., Cummings G. D., al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 1991; 68: 2621–2624
   PubMed Web of Science ®Google Scholar
• Grem J., McAtee N., Murphy R., Hamilton J. M., Balis F., Steinberg S., et al. Phase I and pharmacokinetic study of recombinant human granulocyte–macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol 1994; 12: 560–568
   PubMed Web of Science ®Google Scholar
• Otten H. M., Mathijssen J., ten Cate H., Soesan M., Inghels M., Richel D. J., et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164: 190–194
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Lyman G. H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822–2829
   PubMed Web of Science ®Google Scholar
• Mandala M., Falanga A., Cremonesi M., Zaccanelli M., Floriani I., Viganò M. G., et al. The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma. Thromb Haemost 2006; 95: 752–754
   PubMed Web of Science ®Google Scholar
• Tetzlaff E. D., Correa A. M., Baker J., Ensor J., Ajani J. A. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer 2007; 109: 1989–1995
   PubMed Web of Science ®Google Scholar
• El Accaoui R.N., Shamseddeen W. A., Taher A. T. Thalidomide and thrombosis—a meta-analysis. Thromb Haemost 2007; 97: 1031–1036
   PubMed Web of Science ®Google Scholar
• Kuter D. J. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004; 9: 207–216
   PubMed Web of Science ®Google Scholar
• Vescia S., Baumgartner A., Jacobs V., Kiechle-Bahat M., Rody A., Loibl S., et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol 2008; 19: 9–15
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Venous Thromboembolic Disease, v2.2008, Available at: http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf (accessed September 29, 2008)
   Google Scholar
• Couban S., Goodyear M., Burnell M., Dolan S., Wasi P., Barnes D., et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23: 4063–4069
   PubMed Web of Science ®Google Scholar
• Karthaus M., Kretzschmar A., Kröning H., Biakhov M., Irwin D., Marschner N., et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17: 289–296
   PubMed Web of Science ®Google Scholar
• Verso M., Agnelli G., Bertoglio S., Di Somma F.C., Paoletti F., Ageno W., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057–4062
   PubMed Web of Science ®Google Scholar
• Levine M. N. Adjuvant therapy and thrombosis: how to avoid the problem?. Breast 2007; 16(Suppl 2)169–174
   Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Kuderer N. M., Lyman G. H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–634
   PubMed Web of Science ®Google Scholar
• Weijl N. I., Rutten M. F., Zwinderman A. H., Keizer H. J., Nooy M. A., Rosendaal F. R., et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000; 18: 2169–2178
   PubMed Web of Science ®Google Scholar
• Deitcher S. R., Gomes M. P.V. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 2004; 101: 439–449
   PubMed Web of Science ®Google Scholar
• Pritchard K. I., Paterson A. H., Paul N. A., Zee B., Fine S., Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14: 2731–2737
   PubMed Web of Science ®Google Scholar
• Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 1989; 320: 479–484
   PubMed Web of Science ®Google Scholar
• Fisher B., Dignam J., Wolmark N., DeCillis A., Emir B., Wickerham D. L., et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen-receptor positive breast cancer. J Natl Cancer Inst 1997; 89: 1673–1682
   PubMed Web of Science ®Google Scholar
• The ATAC Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131–2139
   PubMed Web of Science ®Google Scholar
• Brandes A. A., Scelzi E., Salmistraro G., Ermani M., Carollo C., Berti F., et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer 1997; 33: 1592–1596
   PubMed Web of Science ®Google Scholar
• Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Herbst R., Sandler A. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?. Oncologist 2004; 9(Suppl 1)19–26
   PubMedGoogle Scholar
• Rugo H. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004; 9(Suppl 1)43–49
   PubMedGoogle Scholar
• Shah M., Ilson D., Kelsen D. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 2005; 23: 2574–2576
   PubMed Web of Science ®Google Scholar
• Behrendt C. E., Ruiz R. B. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 2003; 90: 734–737
   PubMed Web of Science ®Google Scholar
• Scappaticci F. A., Skillings J. R., Holden S. N., Gerber H. P., Miller K., Kabbinavar F., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232–1239
   PubMed Web of Science ®Google Scholar
• Hussein M. A. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924–930
   PubMed Web of Science ®Google Scholar
• Zangari M., Anaissie E., Barlogie B., Badros A., Desikan R., Gopal A. V., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615
   PubMed Web of Science ®Google Scholar
• Rajkumar S. V., Blood E., Vesole D., Fonseca R., Greipp P.R. Eastern Cooperative Oncology. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Zangari M., Siegel E., Barlogie B., Anaissie E., Saghafifar F., Fassas A., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168–1171
   PubMed Web of Science ®Google Scholar
• Zangari M., Barlogie B., Thertulien R., Jacobson J., Eddleman P., Fink L., et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 4: 32–35
   PubMedGoogle Scholar
• Wun T., Law L., Harvey D., Sieracki B., Scudder S. A., Ryu J. K. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003; 98: 1514–1520
   PubMed Web of Science ®Google Scholar
• Bennett C. L., Silver S. M., Djulbegovic B., Samaras A. T., Blau C. A., Gleason K. J., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914–924
   PubMed Web of Science ®Google Scholar
• Khorana A.A., Kuderer N. M., Culakova E., Lyman G. H., Francis C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902–4907
   PubMed Web of Science ®Google Scholar
• ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of deep vein thrombosis in elective cancer surgery. A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099–1103
   PubMed Web of Science ®Google Scholar
• Bergqvist D., Agnelli G., Cohen A. T., Eldor A., Nilsson P. E., Le Moigne-Amrani A., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975–980
   PubMed Web of Science ®Google Scholar
• Samama M. M., Cohen A. T., Darmon J. Y., Desjardins L., Eldor A., Janbon C., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793–800
   PubMed Web of Science ®Google Scholar
• Leizorovicz A., Cohen A. T., Turpie A. G., Olsson C. G., Vaitkus P. T., Goldhaber S. Z., et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–879
   PubMed Web of Science ®Google Scholar
• Alikhan R., Cohen A. T., Combe S., Samama M. M., Desjardins L., Eldor A., et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341–346
   PubMed Web of Science ®Google Scholar
• Levine M., Hirsh J., Gent M., Arnold A., Warr D., Falanga A., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886–889
   PubMed Web of Science ®Google Scholar
• Falanga A., Rickles F. R. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2007; 165–171
   PubMedGoogle Scholar
• Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlebologie. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006; 25: 101–161
   PubMed Web of Science ®Google Scholar
• Zangari M., Barlogie B., Anaissie E., Saghafifar F., Eddlemon P., Jacobson J., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715–721
   PubMed Web of Science ®Google Scholar